Balversa for FGFR mutated glioms – pro
Balversa (erdafitinib) shows promiseon teh RAGNAR trial for specific gliomas, particularly recurrent IDH-wildtype tumors with FGFR-TACC gene fusions, working by inhibiting the FGFR protein that drives tumor growth, with early trials indicating tolerable side effects and anti-tumor activity, though it’s still under investigation for this use. It’s a targeted therapy requiring genetic testing to identify eligible patients, currently studied in trials like the Phase 2 ETCTN 10559 (part of the RAGNAR trial) for these brain tumors.
Massard C, Pant S, Iyer G, et al. Preliminary results of molecular screening for FGFR alterations in the RAGNAR histology-agnostic study with the FGFR inhibitor (FGFRi) erdafitinib. Poster presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 4-8, 2021; Virtual.
Pant S, Schuler M, Iyer G, et al. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. Lancet Oncol. 2023;24(8):925-935.
Reardon D, Welsh L, Shih K, et al. Efficacy and safety of erdafitinib in patients with high-grade and low-grade gliomas and prespecified fibroblast growth factor receptor alterations (FGFRalt) in the RAGNAR trial. Oral Presentation presented at: Society for Neuro-Oncology